Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim for Prevention of Neutropenia and Radiation Esophagitis in LS-SCLC
NCT04171986Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2019
- Primary completion
- Oct 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Open-label trial of mecapegfilgrastim in neutropenia and radiation esophagitis, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Incidence of neutrophil radiation esophagitis at 6 weeks. Status: unknown.
02
Drugs
mecapegfilgrastim
03
Conditions
neutropeniaradiation esophagitis
Beyond the preview
Go deeper on NCT04171986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171986.